Not actual patients.
For adults with Familial Chylomicronemia Syndrome (FCS),
ON YOUR MARK,GET SET,
Introducing Redemplo®—a new treatment for patients with FCS that reduces triglycerides, and lowered the numerical incidence of acute pancreatitis, with just one dose every 3 months1
Median Reduction in Triglycerides
Achieved significant and sustained reduction in triglycerides from baseline at 10 months1,*
Lowered Numerical Incidence of Acute Pancreatitis
Fewer patients treated with Redemplo experienced acute pancreatitis events than those with placebo: 2 (8%) vs 5 (20%), respectively.1,†
Convenient Dosing
Only Redemplo offers treatment with just one dose every 3 months1
PALISADE was a randomized, placebo-controlled, double-blind trial in adult patients with FCS maintained on a low-fat diet (≤20 grams of fat per day); N=75. The primary endpoint evaluated the median percent change from baseline in fasting triglyceride levels at Month 10.1
*Median fasting triglycerides at baseline were 2008 mg/dL for Redemplo (n=26) and 2053 mg/dL for placebo (n=25). The difference between Redemplo and the placebo group in median percent change in fasting triglyceride levels from baseline to Month 10 was -58.7% (95% CI: -89.6, -27.9; P<0.0001).1
†Over the 12-month treatment period, the numerical incidence of acute pancreatitis in patients treated with Redemplo was lower compared with placebo: 2 (8%) vs 5 (20%), respectively.1
Rely On Redemplo® Patient Support Program
The Rely On Redemplo Patient Support Program provides comprehensive support services to your patients at each stage of the treatment journey with Redemplo
Help your patients start and stay on track with Redemplo.
Start enrolling your patients in the Rely On Redemplo Patient Support Program today.
Get startedJust one dose every 3 months
As an adjunct to diet, Redemplo is self-administered as a single subcutaneous 25-mg injection with just one dose every 3 months.1,2
Are your patients ready for Redemplo?
Not actual patients.
Is Redemplo right for your patients?
Rapid and sustained apoC-III reduction1
AP, acute pancreatitis; CI, confidence interval.
REFERENCES Collapse
Collapse
- Redemplo. Prescribing information. Arrowhead Pharmaceuticals, Inc.; 2025.
- Redemplo. Instructions for use. Arrowhead Pharmaceuticals, Inc.; 2025.
Indication & Important Safety Information
Indication
REDEMPLO® (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Important Safety Information
CONTRAINDICATIONS: None.
ADVERSE REACTIONS: Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and > 5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.